Paladin Labs has launched Silenor (doxepin hydrochloride), specified for the treatment and symptomatic relief of insomnia with characteristics of frequent nocturnal awakening and/or early morning awakenings, in Canada. Silenor, which is ...
Paladin Labs, Somaxon Pharmaceuticals' licensee, has obtained Health Canada approval for Silenor new drug submission. Silenor, a low-dose doxepin oral tablet formulation, is developed to treat insomnia and symptoms such as frequent ...
Mylan Pharmaceuticals has signed a settlement agreement with Somaxon Pharmaceutical to resolve patent litigation related to generic version of Somaxon's Silenor. The litigation is regarding Mylan Pharmaceuticals' abbreviated new drug ...
Tags: litigation, generic version of Somaxon's Silenor, ANDA